Therapeutic targeting of NAT10 with remodelin synergizes with sorafenib to overcome ferroptosis resistance in nasopharyngeal carcinoma by destabilizing SLC7 A11 transcripts [109], while combinatorial inhibition of NAT10 and MDM2 restores wild-type p53 activity in gastric cancer [110]. The gene discussed is NAT10; the disease is gastric cancer.